Search results
Showing 1 to 34 of 34 results for ibs
This guideline covers detecting, diagnosing and treating women (18 years and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (DG44)
Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea
This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
NICE guidance DG11, for the detection of inflammation in the bowel (i.e. IBS vs IBD). Uptake of this guidance has previously been poor...
Improving evidence-based management of irritable bowel syndrome across Somerset
(CG61) in 2008 aiming for appropriate management of irritable bowel syndrome (IBS) within primary care, its recommendations were not...
Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)
We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.
Irritable bowel syndrome in adults: diagnosis and management (CG61)
This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.
This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS134Show all sections
Sections for QS134
- Quality statements
- Quality statement 1: Serological testing for coeliac disease
- Quality statement 2: Referral to a specialist
- Quality statement 3: Endoscopic intestinal biopsy
- Quality statement 4: Advice about a gluten-free diet
- Quality statement 5: Annual review
- Update information
- About this quality standard
management of [Irritable bowel syndrome] (IBS) symptoms, either as first-line therapies in primary care, or in the...
This quality standard covers diagnosing, assessing and managing food allergy in children and young people (under 19) and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS118Show all sections
Sections for QS118
- Quality statements
- Quality statement 1: Allergy-focused clinical history
- Quality statement 2: Diagnosing IgE-mediated food allergy
- Quality statement 3: Diagnosing non-IgE-mediated food allergy
- Quality statement 4: Referral to secondary or specialist care
- Quality statement 5 (placeholder): Diagnosing food allergy in adults
- Quality statement 6 (placeholder): Nutritional support for food allergy
- Update information
differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults with recent onset...
This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS114Show all sections
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Evaluation of guidelines for the use of faecal calprotectin testing in primary care
to support a diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). The Department of...
What is the effect of relaxation and biofeedback therapies on [Irritable bowel syndrome] (IBS) symptoms and patient-related...
and tolerability of bile acid sequestrants among people with irritable bowel syndrome (IBS-D) or Crohn's disease without...
Refractory [Irritable bowel syndrome] (IBS):- What factors contribute to refractory IBS?
CG61/3 Question Refractory [Irritable bowel syndrome] (IBS):- What factors contribute to refractory IBS? Any...
management of [Irritable bowel syndrome] (IBS) symptoms, either as first-line therapies in primary care, or in the...
malabsorption in people with chronic diarrhoea diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without...
is a primary or secondary condition in people diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without...
safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most...
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS54Show all sections
Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making
Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)
This evidence summary has been updated and replaced by NICE guideline CG61.
This guidance has been updated and replaced by NICE diagnostics guidance 44.
This quality standard covers the recognition and initial management of ovarian cancer. It describes high-quality care in priority areas for improvement.
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis.
All NICE products on irritable bowel syndrome. Includes any guidance, advice and quality standards.